Tennessee Dupixent Lawsuit Lawyer | CTCL Lymphoma | One-Year Deadline

Written by Fob James IV, Esq. | Fob James Law Firm, LLC | Last Updated: June 11, 2026

Helping Tennessee Patients Harmed by Dupixent (Dupilumab) Pursue Justice and Compensation

If you or a loved one in Tennessee was prescribed Dupixent (dupilumab) and later developed cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome, you may have grounds to file a Dupixent lawsuit against the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals.

At Fob James Law Firm, our mass tort attorneys represent clients across Nashville, Memphis, Knoxville, Chattanooga, and throughout Tennessee — and in 48 states nationwide. We have recovered over $100 million for more than 1,000 clients in defective drug and product liability litigation. We handle Dupixent cancer claims on a contingency fee basis — you pay nothing unless we win. Important: Tennessee’s one-year filing deadline is one of the shortest in the country, so contact us as soon as possible.

Dupixent Lawsuit Quick Facts

What Is Dupixent, and Why Are Patients Filing Lawsuits?

Dupixent (dupilumab) is an injectable biologic drug manufactured by Sanofi and Regeneron Pharmaceuticals. The FDA approved Dupixent in 2017, and its approved indications have since expanded to include:

• Moderate-to-severe atopic dermatitis (eczema)
• Certain types of asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD)

Dupixent is a blockbuster drug. In 2025, it generated roughly $18 billion in global sales — making it one of the highest-grossing pharmaceutical drugs on the market. Plaintiffs in Dupixent lawsuits allege that these financial incentives contributed to the manufacturers’ failure to disclose a serious cancer risk to patients and prescribers. As of June 2026, the word “lymphoma” does not appear anywhere in Dupixent’s FDA-approved prescribing label.

The lawsuits center on one core allegation: Sanofi and Regeneron knew or should have known that Dupixent could cause, accelerate, or unmask T-cell lymphoma in certain patients — and they failed to warn doctors or patients about this risk.

Does Dupixent Cause Cancer?

Research has linked Dupixent (dupilumab) to a significantly increased risk of cutaneous T-cell lymphoma (CTCL), a rare and aggressive blood cancer that appears on the skin.

Large Database Studies

• JAMA Dermatology (April 2024): Analysis of 19,612 atopic dermatitis patients. Dupixent users showed 4.1x higher odds of developing CTCL (OR 4.1, 95% CI 2.1–8.2) compared to non-users. Most diagnoses occurred more than one year after starting Dupixent.
• Dermatologic Therapy (August 2024): TriNetX study of 1.18 million AD patients. Dupixent linked to 4.6x higher relative risk of CTCL (RR 4.6, 95% CI 2.5–8.6). Highest risk in patients over 60 and within the first year of treatment.
• Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis showing Dupixent had a 30x higher CTCL reporting rate compared to other medications. Proposed mechanism: IL-13 pathway suppression may accelerate malignant T-cell proliferation.
• European Respiratory Journal (June 2025): A population-based cohort of asthma patients (not atopic dermatitis) found Dupixent users faced ~4.5x higher risk of CTCL compared to patients on standard inhaler therapy — extending the risk signal beyond eczema patients.

Case Series and Clinical Reports

• Blood Journal (November 2023): 25 patients at Memorial Sloan Kettering Cancer Center. Median time from Dupixent initiation to CTCL diagnosis: 10 months. Disease progression was often accelerated compared to non-Dupixent CTCL cases.
• JAAD Case Reports (2022): Seven patients with severe atopic dermatitis developed or experienced worsening CTCL after starting Dupixent. Average time to diagnosis: 7.8 months. Biopsies showed unmasking of previously hidden lymphoma.
• International Journal of Dermatology (2023): Systematic review of 18 cases. All had more than 50% body surface involvement before diagnosis; advanced stages (III/IV) were common.

FDA Status and Adverse Event Reports

• March 2025: The FDA formally announced an investigation into Dupixent’s link to CTCL and placed the drug on its watch list for medications with potentially serious risks.
• As of October 2025: The FDA’s FAERS database contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL-specific cases.
• 2026: The FDA continues reviewing reports but has not issued a recall, and the Dupixent label still carries no CTCL/cancer warning — a central allegation in MDL No. 3180.

Cancers Linked to Dupixent: CTCL, PTCL, Mycosis Fungoides, and Sézary Syndrome

Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare form of non-Hodgkin lymphoma involving malignant T-cells that migrate to the skin. In early stages, CTCL can be nearly indistinguishable from eczema or atopic dermatitis — the very condition Dupixent is prescribed to treat. By suppressing skin inflammation, Dupixent may mask the visible signs of an underlying cancer, delaying diagnosis until the disease has progressed. The most common forms include Mycosis Fungoides (the most prevalent, slow-growing form) and Sézary Syndrome (a more aggressive form that spreads to the blood and lymphatic system).

Peripheral T-Cell Lymphoma (PTCL) and Other T-Cell Cancers

In addition to CTCL, Dupixent has been linked to peripheral T-cell lymphoma (PTCL) — a broader and often aggressive category of T-cell malignancy. PTCL is central to the Tennessee litigation: the first Dupixent wrongful death lawsuit in the country, filed in the Middle District of Tennessee, alleges that a woman developed peripheral T-cell lymphoma after starting Dupixent for atopic dermatitis and died within months. In another reported case (a 2026 Illinois lawsuit), a patient received only five Dupixent injections before a PTCL diagnosis requiring chemotherapy and a stem cell transplant. Our firm evaluates both CTCL and PTCL claims for Tennessee residents. The MDL currently focuses on CTCL, but the Panel left open the possibility that other T-cell lymphomas, including PTCL, may be added through the conditional-transfer process.

Why Dupixent Makes CTCL So Difficult to Diagnose

The most insidious aspect of the Dupixent–CTCL link is the diagnostic gray zone between eczema and early-stage cutaneous T-cell lymphoma. Both conditions present with red, inflamed, itchy skin patches; scaly or crusted plaques; thickened, leathery skin; symptoms that flare and subside; and partial response to topical steroids.

Because eczema and early CTCL look nearly identical — even on biopsy in some cases — patients who actually have CTCL are regularly diagnosed with eczema and prescribed Dupixent. When Dupixent suppresses the visible inflammation, the improvement appears to confirm the eczema diagnosis. But if the underlying condition is CTCL, the cancer continues to advance beneath the surface. By the time the true diagnosis is made, patients are often at a more advanced and dangerous stage.

Warning Signs and Symptoms of Dupixent-Associated Lymphoma

If you have taken Dupixent and experience any of the following, consult your physician. Do not stop or change your Dupixent use without medical guidance — but do request evaluation for lymphoma:

• New or worsening skin patches, plaques, or nodules that are scaly, itchy, or burning
• Persistent red or purple lesions that do not respond to eczema treatments as expected
• Thickened or tumorous skin areas, especially on sun-protected surfaces
• Swollen lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, persistent night sweats, or recurring fevers (“B symptoms”)
• Eczema that initially improves, then worsens in an unusual or atypical pattern

Litigation Updates: Dupixent Lawsuit & Regulatory Timeline

June 2026 update — the Dupixent MDL is now active, and Tennessee helped start it. On June 4, 2026, the JPML created MDL No. 3180 in the District of New Jersey under Judge Zahid N. Quraishi, consolidating federal lawsuits alleging Dupixent caused or accelerated T-cell lymphoma. Tennessee holds a notable place in this litigation: the first Dupixent wrongful death lawsuit in the country was filed here, in the Middle District of Tennessee, in October 2025.

Notable Dupixent Lawsuits

• First wrongful death filed in Tennessee (October 2025): The nation’s first Dupixent wrongful death lawsuit was filed in the U.S. District Court for the Middle District of Tennessee. The complaint alleges a woman began Dupixent injections for adult-onset atopic dermatitis in May 2024, developed peripheral T-cell lymphoma, and died in October 2024 — and that Regeneron and Sanofi-Aventis failed to warn about the lymphoma risk. This case put Tennessee at the forefront of the Dupixent litigation.
• Nationwide growth: As additional CTCL cases were filed across the country — heavily concentrated in Georgia — attorneys moved to consolidate them, leading to the creation of MDL No. 3180 in June 2026.

These cases reflect a consistent pattern: patients with no prior cancer history who developed aggressive T-cell lymphoma after starting Dupixent, and families who allege the manufacturers never warned them.

What Claims Are Brought in a Dupixent Lawsuit?

Dupixent lawsuits allege that Sanofi and Regeneron:

• Failed to warn patients and prescribers about the risk of CTCL and PTCL despite available evidence — the primary failure-to-warn theory under Tennessee products liability law.
• Marketed Dupixent aggressively to maximize revenue while suppressing or ignoring emerging cancer signals.
• Failed to require prescreening (such as T-cell clonality testing or skin biopsy) before starting Dupixent in higher-risk patients.
• Failed to include a “stop and investigate” protocol when symptoms did not follow the expected eczema progression.
• Failed to update the label despite hundreds of adverse event reports.
• In wrongful death cases: caused or substantially contributed to deaths where CTCL or PTCL was delayed in diagnosis or accelerated by Dupixent — as alleged in the first U.S. Dupixent wrongful death case, filed in Tennessee.

These claims arise under product liability law — failure-to-warn, design defect, and negligence — under Tennessee law and the laws of other states where clients reside.

Who Can File a Dupixent Lawsuit in Tennessee?

You may be eligible to file a Dupixent injury lawsuit in Tennessee if:

• You were prescribed Dupixent for an approved condition (eczema/atopic dermatitis, asthma, nasal polyps, EoE, COPD, prurigo nodularis, or another indication).
• You were later diagnosed with CTCL, PTCL, mycosis fungoides, Sézary syndrome, or another T-cell or NK-cell malignancy.
• Your cancer diagnosis occurred during or after your Dupixent treatment, or your pre-existing lymphoma was allegedly accelerated or unmasked by Dupixent.
• You have medical records — including pathology reports — documenting both your Dupixent use and your diagnosis.
• You live in Tennessee, were prescribed Dupixent in Tennessee, or were treated for your lymphoma in Tennessee — including Nashville, Memphis, Knoxville, and Chattanooga.
• You can file before Tennessee’s short one-year statute of limitations expires.

Family members of Tennessee patients who died from T-cell lymphoma linked to Dupixent may also have standing to file wrongful death claims. Because Tennessee’s deadline is so short, contact our firm immediately.

What Compensation Can Tennessee Dupixent Victims Recover?

Victims of Dupixent-related cancer injuries in Tennessee may be entitled to recover:

• Medical expenses — past treatment costs (chemotherapy, radiation, stem cell transplants) and future care
• Lost wages and loss of future earning capacity
• Pain and suffering
• Emotional distress and psychological harm
• Loss of enjoyment of life
• Wrongful death damages — for family members of deceased victims, including funeral expenses and loss of consortium

Each case is highly fact-specific. Our attorneys will evaluate your complete medical history during a free case review.

Tennessee Statute of Limitations for Dupixent Drug Injury Claims

Under Tenn. Code Ann. § 28-3-104, personal injury claims in Tennessee generally must be filed within one year from the date of injury or the date you discovered (or reasonably should have discovered) the connection between Dupixent and your diagnosis — one of the shortest deadlines in the country. Tennessee’s product liability statute (Tenn. Code Ann. § 29-28-103) can allow claims up to six years, subject to a 10-year statute of repose, but the one-year personal injury clock is the critical deadline for most Dupixent claimants.

That means time is extremely limited. Even if you are not sure exactly when Dupixent caused your condition, contact Fob James Law Firm at 866-837-1010 immediately — waiting even a few months could permanently bar your claim.

What Should You Do if You Used Dupixent and Developed CTCL?

1. Consult your physician before stopping Dupixent. Do not discontinue without medical supervision.
2. Request a complete copy of your medical records, including dermatology notes, pathology reports, and oncology treatment records.
3. Document your timeline: when you started Dupixent, your dosage and frequency, when symptoms changed, and when you were diagnosed.
4. Preserve all prescription records and pharmacy receipts related to Dupixent.
5. Contact Fob James Law Firm at 866-837-1010 for a free, confidential evaluation — and act quickly, because Tennessee’s one-year deadline is short.
6. Do not provide recorded statements to Sanofi, Regeneron, or their insurers without speaking to an attorney first.

Frequently Asked Questions About Dupixent Lawsuits in Tennessee

Is there a Dupixent recall in 2026? No. As of June 2026, the FDA has not recalled Dupixent. The agency formally announced an investigation in March 2025 and continues to monitor adverse event reports of CTCL and other lymphomas. Dupixent remains on the market with no cancer warning on its label.

What cancers are linked to Dupixent? The primary cancers linked to Dupixent are cutaneous T-cell lymphoma (CTCL) — including mycosis fungoides and Sézary syndrome — and peripheral T-cell lymphoma (PTCL). The first Dupixent wrongful death case, filed in Tennessee, involved PTCL.

Is there a Dupixent MDL or class action? There is now a Dupixent MDL — but it is not a class action. On June 4, 2026, the JPML established MDL No. 3180 in the District of New Jersey before Judge Zahid N. Quraishi. Each plaintiff keeps their own individual case. Tennessee is already part of this litigation — the first Dupixent wrongful death lawsuit in the country was filed in Tennessee. If you file now, your case can be filed into or transferred to MDL No. 3180.

Can I file a Dupixent lawsuit if I live outside Tennessee? Yes. Fob James Law Firm represents Dupixent clients in 48 states. We are licensed in Tennessee, Alabama, and Georgia, and co-counsel with qualified attorneys in other jurisdictions where required.

How long does a Dupixent lawsuit take? Mass tort pharmaceutical cases typically take several years. Now that the MDL is formed (June 2026), bellwether trials and early settlements may occur within 2–3 years of centralization. Filing now preserves your claim and improves your positioning.

What is the statute of limitations for a Dupixent claim in Tennessee? Tennessee has one of the shortest deadlines in the country — generally one year from injury or discovery (Tenn. Code Ann. § 28-3-104). Product liability claims may extend up to six years subject to a 10-year statute of repose, but the one-year personal injury clock is critical. Contact an attorney immediately.

What does it cost to hire a Dupixent lawyer at Fob James Law Firm? Nothing upfront. We handle all Dupixent cases on a contingency fee basis. If we do not recover compensation for you, you owe us nothing.

Is the Dupixent label defective? Plaintiffs argue yes. As of June 2026, the FDA-approved Dupixent prescribing information does not mention CTCL, PTCL, mycosis fungoides, Sézary syndrome, or the word “lymphoma” at all — despite hundreds of adverse event reports and multiple peer-reviewed studies establishing a statistical association.

Can the family of someone who died from Dupixent-linked lymphoma file a lawsuit? Yes. Family members of patients who died from CTCL or PTCL allegedly linked to Dupixent may file a wrongful death lawsuit in Tennessee. In fact, the first Dupixent wrongful death lawsuit in the country was filed in Tennessee in October 2025. Contact us to evaluate your family’s options — Tennessee’s one-year deadline makes acting quickly essential.

I was prescribed Dupixent for asthma, not eczema. Can I still sue? Potentially yes. A June 2025 study published in the European Respiratory Journal found that Dupixent users with asthma faced ~4.5x higher risk of CTCL than patients on other asthma medications. The cancer risk signal is not limited to eczema patients.

How do I start a Dupixent claim in Tennessee? Call us at 866-837-1010 or complete our online case evaluation form. Because Tennessee’s one-year deadline is short, contact us as soon as possible. Our team will review your medical history, explain your rights, and guide you through every step — at no charge until we win.

What is the average Dupixent settlement? No Dupixent cases have settled or gone to trial yet, so there is no average settlement figure. Now that cases are consolidated in MDL No. 3180, the litigation will move through discovery, expert (Daubert) rulings, and bellwether trials — the points at which settlement values typically come into focus. Settlement amounts generally turn on the severity of the diagnosis, the cost of treatment, the strength of the failure-to-warn evidence, and whether the case involves a wrongful death.

Contact a Tennessee Dupixent Lawsuit Lawyer Today — Free Consultation

If you or a family member developed T-cell lymphoma, CTCL, PTCL, mycosis fungoides, or Sézary syndrome after taking Dupixent, don’t wait. Tennessee’s one-year deadline is one of the shortest in the country — every day you delay could affect your ability to recover compensation.

Call Fob James Law Firm at 866-837-1010 or complete our online form for a free, confidential case evaluation. We serve clients throughout Tennessee, including Nashville, Memphis, Knoxville, and Chattanooga — and represent clients nationwide in 48 states.

Our Dupixent lawsuit lawyers are ready to fight for your rights and hold Sanofi and Regeneron accountable.

Related: Alabama Dupixent Lawsuit | Georgia Dupixent Lawsuit | Tennessee Depo-Provera Lawsuit